GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A3895 TUG-770Target: Free Fatty Acid ReceptorsSummary: FFA1/GPR40 agonist -
A3918 VilazodoneSummary: Combined SSRI and 5-HT1A receptor partial agonist -
A3919 Vilazodone HydrochlorideSummary: Combined SSRI and 5-HT1A receptor partial agonist -
A3926 VortioxetineTarget: 5-HT1 Receptors|5-HT7 Receptors|5-HT3 Receptors|SERTSummary: 5-HT receptors antagonist -
A4233 MethylprednisoloneTarget: Glucocorticoid ReceptorsSummary: Apoptosis inducer,GR agonist -
A3125 5-IodotubercidinTarget: Adenosine KinasesSummary: Adenosine kinase inhibitor,potent -
A3147 AH 6809Summary: EP and DP receptor antagonist -
A3159 Alosetron HydrochlorideSummary: 5-HT3 receptor antagonist,potent and highly selective -
A3166 AM0953 CitationSummary: Potent LPA1 receptor antagonist -
A3167 AM-095 free baseTarget: LPA ReceptorsSummary: Potent LPA1 receptor antagonist

